AbbVie shares slip 4% as Q2 immunology earnings beat falls short of lofty expectations

AbbVie’s stock fell about 4% on Friday after the company reported second‑quarter results that modestly exceeded analyst forecasts, disappointing investors who had set very high expectations.

The firm’s immunology and inflammation portfolio topped consensus estimates by roughly one percent, a performance described by BMO Capital Markets as a beat that was less robust than the market typically expects from AbbVie.

The decline was amplified by a slight reduction in the company’s earnings‑per‑share guidance, which was trimmed by four cents to a range of $13.87‑$14.07. Analysts noted the adjustment stemmed from the accounting impact of the recent Apogee acquisition.

Revenue from the I&I segment reached $8.79 billion, a 15% year‑over‑year increase. Humira generated $756 million, beating expectations by three percent, while Skyrizi contributed $5.5 billion.